Systematic review on PK of CefpodoximeClinical pharmacokinetics of cefpodoxime: a systematic review

ABSTRACT

Introduction

Cefpodoxime, a third-generation cephalosporin, is a broad-spectrum antibiotic widely used to treat acute upper respiratory tract infections (RTI). This systematic review aims to present a comprehensive view of all the available pharmacokinetics (PK) data associated with the pharmacodynamics (PD) parameters of cefpodoxime in humans.

Areas Covered

The PubMed, Google Scholar, Cochrane Library, and Science Direct, were systematically searched to identify studies on the PK of cefpodoxime. Out of 746 papers, 26 articles meeting the eligibility criteria were included that have reported the PK data. The drug exposure for the patients undergoing hemodialysis was 50% lower than healthy participants. The renal clearance was almost 27% less in pediatric patients than in adults. The plasma concentrations of cefpodoxime exceeded the minimum inhibitory concentration (MIC) for 90% of skin pathogens, including Streptococcus species and Staphylococcus species (i.e.) < 1 μg/mL and 2–4 μg/mL respectively.

Expert Opinion

The current study includes detailed information on clinical PK of cefpodoxime in healthy, diseased, pediatric populations as well as drug-drug interactions and drug-food interactions. Moreover, this systematic review also explicated PK/PD properties of drug with a specific impact on MIC of drug. The present review will also assist clinicians in the development of PK models for cefpodoxime.

KEYWORDS:

• Cefpodoxime
• clearance, MIC, pharmacokinetics
• respiratory tract infection
• systematic review

Disclaimer

As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.

Article Highlights

• Cefpodoxime is a third-generation cephalosporin antibiotic that has been employed for the treatment of acute upper RTI.

• This is the first systematic review of cefpodoxime clinical PK covering all studies in healthy and diseased populations including drug-drug interaction, and drug-food interaction, with associated PK/PD properties such as MIC.

• Cefpodoxime’s PK studies can assist researchers and clinicians in modifying dosage for patients with renal impairment.

• The provided PK data can benefit researchers in developing and evaluating PK models for cefpodoxime.

Declaration of Interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Authors’ contributions statement

All authors have contributed substantially to the design, extraction, analysis, and interpretation of data and have actively participated in drafting and revising the article. All authors agreed to submit the final version to the journal and agreed to be accountable for all aspects of the work.

Availability of data and materials

All data generated or analyzed during this study are included in the article or its supplementary information file.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/17425255.2024.2391389.

Additional information

Funding

This paper is not funded.